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Abstract
Vascular endothelial growth factor-A (VEGF-A) is required for vascular development throughout the embryo and has been proposed to
play an important role in pulmonary vascular patterning. Expressed by the embryonic respiratory epithelium, VEGF-A signals endothelial
cells within the splanchnic mesenchyme. To refine understanding of the spatial and temporal role of VEGF-A in lung morphogenesis,
isoform VEGF164 was expressed under conditional control in distal and proximal airway epithelial cells. Unexpectedly, increased
expression of VEGF164 in distal lung disrupted peripheral vascular net assembly and arrested branching of airways tubules without altering
endothelial cell proliferation or apoptosis. Peripheral airway branching and vascular smooth muscle patterning were also altered. In contrast,
expression of VEGF164 by epithelial cells of the conducting airways caused atypical evaginations of small capillary-like vessels into large
airways but did not alter peripheral vascular net assembly or branching morphogenesis. These data demonstrate that the differential response
of endothelial cells in distal vascular beds and large central blood vessels is established early in lung development. Precise temporal and
spatial expression of VEGF-A is required for vascular patterning during lung morphogenesis. Disruption of pulmonary vascular assembly
perturbs reciprocal interactions with epithelium leading to altered airway branching morphogenesis.
© 2003 Elsevier Inc. All rights reserved.
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Introduction
Pulmonary vascular development is a complex biological
process involving the coordination of reciprocal interactions
between diverse tissues and cells. The temporal and spatial
pattern of vascular endothelial growth factor A (VEGF-A)
expression during lung organogenesis (Ng et al., 2001; Park
et al., 1993) suggests it is a factor in the reciprocal interac-
tions between airway epithelium and the vascular endothe-
lium through control of pulmonary vascular pattern forma-
tion and alveolar-capillary interactions. When VEGF-A is
expressed throughout lung organogenesis, vascular struc-
tures are perturbed and branching morphogenesis disrupted
(Zeng et al., 1998). However, little is known of the cellular
and morphogenic events regulated by VEGF-A during for-
mation of proximal and distal pulmonary vascular beds.
Several lines of evidence support the critical role of
VEGF-A in vascular morphogenesis. First, VEGF-A and its
high affinity receptors VEGFR1 (flt-1) and VEGFR2 (flk-1)
are colocalized in regions of vessel formation (Miquerol et
al., 1999). VEGF-A is essential for embryogenesis, as mice
deficient in either VEGF-A (Carmeliet et al., 1996; Ferrara
et al., 1996) or its receptors (Fong et al., 1995, 1999;
Shalaby et al., 1995) have severe vascular defects that are
lethal by embryonic day E8.5 to E9. Increased expression of
VEGF-A also disrupts embryonic development causing le-
thal heart defects by E14 (Miquerol et al., 2000).
Vascularization of the lung occurs through both vascu-
logenesis and angiogenesis, processes regulated by
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VEGF-A (Carmeliet et al., 1999; Shalaby et al., 1995).
Angiogenesis proceeds by sprouting and remodeling from
existing vessels. In the developing mouse lung, angiogene-
sis is first detected at E11, when sprouting of central pul-
monary arteries occurs (deMello et al., 1997). Vasculogen-
esis is the process of differentiation of angioblast precursors
in the mesenchyme to form endothelial cells. Through mi-
gration and angiogenesis, these cells form clusters and as-
semble into a primitive vascular network. This vascular
network is detected as early as E10.5 in distal lung mesen-
chyme and will become the distal capillary bed (Schachtner,
2000). The pulmonary circulation is established by fusion of
the peripheral vascular net with central vessels. Rapid vas-
cular net expansion and connections between peripheral and
Fig. 1. Conditional regulation of VEGF-A. (A) Constructs used to generate the lung-specific, doxycycline-regulatable VEGF164 transgene expression.
SP-CrtTA and CCSPrtTA constructs described in Tichelaar et al., 2000. The (tetO)7VEGF construct has 7 copies of the tetracycline operator (tetO), minimal
CMV promoter (minCMV), cDNA for murine VEGF-A isoform V164, and bovine growth hormone polyadenylation sequence (bGHpA). (B) VEGF-A in
E16.5 lung lysates was determined by ELISA and normalized to total protein. The VEGF-A levels in lung were: for nontransgenic animals 119  26 pg/mg
of protein (n  7); for single transgenic (tetO)7VEGF animals on doxycycline E10.5 to E16.5, 148  8 pg/mg of protein (n  3); for bitransgenic
SP-CrtTA/(tetO)7VEGF animals on doxycycline E10.5 to E16.5, 479  117 pg/mg of protein (n  5); for bitransgenic CCSPrtTA/(tetO)7VEGF animals on
doxycycline E10.5–E16.5, 355  55 (n  8). Immunohistochemistry for VEGF-A in E16.5 lung from (C) nontransgenic, (D) SP-CrtTA/(tetO)7VEGF, and
(E) CCSPrtTA/(tetO)7VEGF animals treated in utero with doxycycline from E10.5 to E16.5. Inset in D shows bronchus from the same section. epi, distal
airway epithelium; br, bronchioli and bronchi; m, mesenchyme. Scale bar for D and E shown in panel E.
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central vascular systems occurs in the pseudoglandular stage
(E10 to E16) of lung morphogenesis. In this period increased
expression of VEGF-A occurs in peripheral respiratory epithe-
lial cells. Epithelial tubules and the vascular net become
closely apposed as the gas exchange region is formed (deMello
et al., 1997). It has been proposed that epithelial expression of
VEGF-A establishes a morphogenic gradient that mediates
these interactions (Ng et al., 2001; Park et al., 1993).
VEGF-A isoforms, generated by alternate splicing, differ
in receptor affinity, heparin binding, and solubility (Neufeld
et al., 1999; Robinson et al., 2001). The subset and location
of VEGF-A isoform expression shifts during lung morpho-
genesis. At early stages, before E12.5, the diffusible isoform
VEGF-A120 (VEGF120) and, with intermediate diffusibil-
ity, the isoform VEGF-A164 (VEGF164) are expressed by
cells in both the mesenchyme and epithelium (Greenberg et
al., 2002). However, by E14.5, midway through the pseu-
doglandular stage, high levels of VEGF-A188 (VEGF188),
with high affinity heparin binding, as well as VEGF164 are
expressed by subsets of peripheral respiratory epithelial
cells. The affinity of VEGF164 and VEGF188 for matrix
components is proposed to generate localized areas of in-
creased concentration of VEGF-A and establishment of a
gradient around the tips of the expanding airways (Ng et al.,
2001; Park et al., 1993).
To more clearly define the temporal and spatial param-
eters through which VEGF-A influences pulmonary vascu-
lar development, we expressed VEGF164 under control of
doxycycline-inducible, lung-specific transgenes in the
mouse embryo. Analysis shows differential response of
large central vessels and the distal capillary bed to increased
VEGF-A. We define a critical period during which epithe-
lial expression of VEGF-A modulates vascular bed assem-
bly without altering endothelial cell proliferation. These
studies suggest that pulmonary vascular assembly indirectly
influences the patterning of peripheral airways and pulmo-
nary vascular smooth muscle.
Methods and materials
Conditional, lung-specific transgenic mice
In the construct used to generate the (tetO)7VEGF trans-
genic mice, cDNA for the murine VEGF-A isoform
VEGF164 was inserted between the (tetO)7CMV minimal
promoter and the bovine growth factor polyadenylation sig-
nal sequence (bGHpA) described previously (Clark et al.,
2001; Tichelaar et al., 2000). Plasmid constructs were ver-
ified by sequencing and microinjected into mouse oocytes
from the FVB/N strain using standard procedures. Southern
analysis of genomic DNA was used to identify transgenic
animals. Two independent transgenic lines with inducible
VEGF164 expression were identified. Histological findings
were similar in both lines. Line 90 was selected for further
study because of consistent success in breeding. All het-
erozygous and homozygous mice were viable and had no
malformations. In the activator mice, the rtTA gene, under
control of the human 3.7-kb surfactant protein C (SP-C)
promoter, selectively directs expression of transgenes in
subsets of nonciliated epithelial cells of the peripheral lung.
The 2.3-kb rat Clara cell secretory protein (CCSP) promoter
directs expression to proximal, conducting airway epithe-
lium (Stripp et al., 1992).
Single transgenic mice bearing either the SP-CrtTA
transgene or CCSPrtTA transgene were bred to single trans-
genic mice bearing the (tetO)7VEGF transgene to generate
bitransgenic progeny. In the experiments described here
SP-CrtTA or CCSPrtTA males were bred to (tetO)7VEGF
females. Genotyping was done by PCR using primers spe-
cific for each transgene. The primers are: SP-CrtTA,
5-GACACATATAAGACCCTGGTCA and 5-AAAAT-
CTTGCCAGCTTTCCCC; (tetO)7VEGF, 5-GTGCACTG-
GACCCTGGCTTTA CTG and 5-ATGTGCTGGCTTTG-
GTGAGGTTTG. For CCSPrtTA/(tetO)7VEGF embryos,
the primers are: 5-ACTGCCCATTGCCCAAACAC and
5-AAAATCTTGC CAGCTTTCCCC. To induce transgene
expression in double transgenic embryos, pregnant females
were given doxycycline administered in the food pellets at
a concentration of 0.6 mg/g (Harlen Teklar, Madison, WI)
for specified time periods. Transgene expression is detected
in the lung 6 to 12 h after administration of doxycycline
(Perl et al., 2002). VEGF-A transgene expression was quan-
tified from embryonic lung lysates with Quantikine ELISA
kit (R&D Systems, Minneapolis, MN) following manufac-
turer’s instructions. For analysis described here, line 90 with
2- to 4-fold induction over nontransgenic expression was
used. The flk.LacZ animals from Jackson Laboratories were
identified using tissue from the tails and enzymatic detec-
Fig. 2. Differential response of proximal and distal lung to VEGF164. Embryonic lungs from (A–D) nontransgenic (NT), (E–K) CCSPrtTA/(tetO)7VEGF,
and (L–O) SP-CrtTA/(tetO)7VEGF animals. Dams for all animals were treated with doxycycline from E10.5 until embryonic lungs were collected at either
E16.5 or E18.5 as indicated. At E16.5, nontransgenic (A) and CCSPrtTA/(tetO)7VEGF mice (E) had similar lung size and morphology, while SP-CrtTA/
(tetO)7VEGF animals (L) had similar size but dilated airway tubules (arrowheads in L). Distal epithelial (epi) tubules of NT (B) and CCSPrtTA/(tetO)7VEGF
(F) lung were surrounded by PECAM staining, marking endothelial cells of the vascular net (arrows). In SP-CrtTA/(tetO)7VEGF lung (M) few
PECAM-stained cells were detected in distal mesenchyme. Bronchi and bronchioli (br) of NT (C) and SP-CrtTA/(tetO)7VEGF (N) were accompanied by
vessels (v) but separated from endothelial cells by mesenchymal cells. In CCSPrtTA/(tetO)7VEGF lungs, PECAM-stained cells (arrows in G) directly
contacted and invaded the epithelium of the bronchi (br). At E18.5 (H) the bronchi (br) of CCSPrtTA/(tetO)7VEGF animals had multiple evaginations into
the airway lumen. Immunostaining of consecutive sections with (I) PECAM, (J) SM  actin, and (K) CCSP indicated that the evaginations (*) had
capillary-like vessels in close apposition to CCSP-stained bronchial epithelium. (J) Actin-staining smooth muscle cells encircled the bronchi. (O) At E18.5
distal airway epithelial tubules (epi) of SP-CrtTA/(tetO)7VEGF animals were dilated, with poor branching compared to (D) airways of NT animals.
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tion of -galactosidase (gal) activity as described below.
All transgenic animals were kept in pathogen-free vivarium
according to institutional guidelines.
Tissue preparation, histology, and immunohistochemistry
To obtain fetal lung tissue, the embryos were removed by
hysterectomy after euthanasia of the dam by CO2 inhalation.
Embryonic lungs were fixed in 4% paraformaldehyde and
paraffin embedded as described previously (Greenberg et
al., 2002). For histology, 4-m sections were stained with
hematoxylin/eosin (H/E). For immunohistochemistry the
primary antibodies were: for PECAM-1, Mec 13.3 (BD
Biosciences PharMingen, San Diego, CA); for VEGFR2,
sc315 (Santa Cruz BioTech, Santa Cruz, CA); for VEGF-A,
sc152 (Santa Cruz); for cytokeratin, Ab PCK-26; and for 
smooth muscle actin, Ab4A1 (Sigma, St. Louis, MO); for
proSP-C Ab3428 (Chemicon, Temecula, CA). Endothelial-
specific lectin staining (Ponder et al., 1985) was done with
FITC-conjugated GSL-B4 isolectin (Vector Labs, Burlin-
game, CA) with 10 mM CaCl2 and 20 mM MgCl2. To
analyze proliferation, pregnant dams were injected intra-
peritoneally (i.p.) with bromodeoxyuridine (BrdU) at 1 g/g
of weight and embryos collected 2 h later. BrdU-labeled
cells were detected by immunostaining with BrdU Staining
Kit from Zymed (San Francisco, CA). Proliferation index
was determined by counting BrdU-positive cells and total
cells in five independent areas for each of four different
animals in each treatment group.
-Galactosidase analysis
Lungs were dissected from embryos and fixed with 0.2%
glutaraldehyde and 2% paraformaldehyde for 2 h and incu-
bated with O-nitrophenyl--D-galactoside (X-Gal) substrate
(Schachtner et al., 2000) for 2 to 6 h. Following brief
washing with phosphate-buffered saline, lungs were exam-
ined with a Nikon inverted microscope and the image re-
corded with a digital camera. For quantification of gal,
lung lysates were prepared and analyzed using X-Gal sub-
strate. After incubation at 37°C for 15 min, optical density
at 420 nm was determined. Total protein per lung was
determined by BCA analysis (Pierce, Rockford, IL). To
normalize results from different animals to a common pa-
rameter indicative of cell number, activity is reported as
gal OD units/g of total protein per lung.
Results
Conditional control of VEGF164 expression in developing
lung
VEGF164 was expressed under conditional control of
the SP-C and CCSP promoters (Fig. 1A) from E10.5 to
E16.5. This period covers the late embryonic and pseu-
doglandular stages of lung development, a period of rapid
vascular morphogenesis and airway branching. Treatment
of dams with doxycycline induced VEGF164 expression in
embryonic lungs. In control lung, VEGF-A is expressed by
mesenchyme and epithelium (Greenberg et al, 2002). After
E14.5, peripheral airway epithelial cells are the predominant
site of expression, (E16.5 lung in Fig. 1C). When SP-
CrtTA(tetO)7VEGF mice were exposed to doxycycline from
E10.5 to E16.5, VEGF-A protein was detected in peripheral
respiratory epithelial cells but not detected in cells of prox-
imal airway, Fig. 1D. Treatment of CCSPrtTA(tetO)7VEGF
mice from E10.5 to E16.5 induced expression of VEGF164
by conducting airway epithelial cells (Fig. 1E), without
altering expression of endogenous VEGF-A by epithelial or
mesenchymal cells.
Quantification of VEGF164
ELISA analysis was used to determine the concentration
of VEGF-A in lungs of SP-CrtTA/(tetO)7VEGF and
CCSPrtTA/(tetO)7VEGF mice. At E16.5 homogenates were
prepared from lungs of nontransgenic (NT) and bitransgenic
mice treated with doxycycline from E10.5 to E16.5. There
was no significant difference in lung VEGF-A in nontrans-
genic and single transgenic pups. In SP-CrtTA/(tetO)7VEGF
lungs, VEGF-A levels increased approximately 3-fold after
administration of doxycycline. In bitransgenic CCSPrtTA/
(tetO)7VEGF mice, doxycycline treatment induced lung
VEGF-A levels approximately 2.5-fold above levels for
nontransgenic mice.
Pulmonary vascular responses to VEGF164 are
dependent on site of expression
To determine the effects of altered spatial expression of
VEGF164, bitransgenic animals were treated with doxycy-
cline from E10.5 to E16.5. Expression of VEGF164 in
either proximal [in CCSPrtTA/(tetO)7VEGF] or peripheral
[in SP-CrtTA/(tetO)7VEGF] epithelial cells did not alter
lung size, Fig. 2A, E, and L, but altered vascular patterning
in distinct ways. At E16.5 lung, endothelial cells, detected
by immunohistochemistry for PECAM, surround peripheral
lung tubules in the normal lung (Fig. 2B). In proximal lung,
endothelial cells assemble into vessels with defined lumens
near the conducting airways (Fig. 2C). Neither the large
vessels nor the vascular net have direct contact with airway
epithelial cells.
In CCSPrtTA/(tetO)7VEGF mice, expression of
VEGF164 from E10.5 to E16.5 did not alter peripheral
vascular net formation and airway morphogenesis (Fig. 2F).
However, VEGF induction in proximal epithelium caused
irregular evagination of epithelium into the lumen of bron-
chi and bronchioli (Fig. 2G). With VEGF164 induction
from E10.5 to E18.5, there were multiple evaginations con-
taining capillary-like vessels. Many of the vessels had lu-
mens and were in close apposition to the bronchial epithe-
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lium (Fig. 2H–J). Smooth muscle cells encircled the bronchi
but were not detected in the evaginations. (Fig. 2J).
In contrast, in SP-CrtTA/(tetO)7VEGF animals treated
with doxycycline from E10.5 to E16.5, peripheral lung
morphogenesis was altered with disrupted vascular pattern
formation. Few PECAM-stained endothelial cells were de-
Fig. 4. After E12.5 airway morphology and vascular assembly permanently disrupted by increased VEGF164. SP-CrtTA/(tetO)7VEGF mice were given doxycycline
in utero either E12.5 to E14.5 or E14.5 to E16.5. Lungs from all embryos were collected at E16.5 and analyzed by (A, D, and G) H/E staining and immunostaining
for (B, E, and H) PECAM and (C, F, and I) isolectin FITC-GSL B4 (Ponder et al., 1985). Dilated epithelial airway tubules (arrows in D and G) were evident at
E16.5 after induction from either (D) E12.5 to E14.5 or (G) E14.5 to E16.5. In C, F, and I epithelial cells were identified by immunostaining with Texas
Red-conjugated antibody to cytokeratin. In nontransgenic E16.5 lung (B and C), endothelial cells encircled distal epithelial tubules (epi), forming a vascular network.
Vascular net formation was significantly altered with VEGF-A overexpression from (E and F) E12.5 to E14.5 and (H and I) E14.5 to E16.5. Few endothelial cells
were detected in distal lung (brackets F and I) and the vascular net was highly disordered (arrows, E, F, H, and I).
Fig. 3. VEGF164 alters vascular assembly. Pregnant mice with potential flk.LacZ and SP-CrtTA/(tetO)7VEGF/flk.LacZ offspring were given doxycycline from E10.5
to E12.5 and the embryonic lungs collected at E12.5. Pulmonary vascular net was analyzed in lung (A, B, D, and E) whole mount and (C and F) thin sections by
detection of gal activity. (A, B, and C) In nontransgenic animals the vascular net surrounded each budding epithelial tubule (epi). (D, E, and F) In lungs from
SP-CrtTA/(tetO)7VEGF mice, gal endothelial cells were absent from the distal mesenchyme (m) around epithelial tubules (epi). The primary pulmonary vessels
are indicated with white arrows (A and D). (G and H) VEGF-A immunostaining in E12.5 lung in nontransgenic (G) and SP-CrtTA/(tetO)7VEGF lung (H) treated
in utero with doxycycline E10.5 to E12.5. (I and J) Alterations in vascular net patterning were reversible. Nontransgenic and SP-CrtTA/(tetO)7VEGF littermates were
treated in utero with doxycycline chow from E10.5 to E12.5 and normal chow from E12.5 to E16.5 and lungs collected at E16.5. The PECAM-stained vascular net
was perturbed in only a few areas (arrow in J) of SP-CrtTA/(tetO)7VEGF lung. (K–N) Overlapping expression of PECAM and VEGFR2 by endothelial cells in the
vascular net. Immunostaining showed coincident PECAM (arrows in K and M) and VEGFR2 (arrows in L and N) on consecutive sections in (K and L) NT lung
and coincident but diminished staining in (M and N) SP-CrtTA/(tetO)7VEGF lung.
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tected in the mesenchyme of peripheral lung (Fig. 2M).
Small clusters of endothelial cells were observed within the
mesenchyme and the peripheral vascular net was not con-
tinuous around the developing tips of distal airway tubules.
At both E16.5 (Fig. 2L) and E18.5 (Fig. 2O), airway branch-
ing was reduced and peripheral tubules were dilated.
Branching of large airways and vascular patterning of prox-
imal lung were not altered in SP-CrtTA/(tetO)7VEGF mice
at E16.5 (Fig. 2N). The marked differences in response to
expression by proximal versus distal epithelium suggests
that the effect of VEGF164 is spatially restricted to the site
of synthesis. The distinct phenotypes seen in SP-CrtTA/
(tetO)7VEGF and CCSPrtTA/(tetO)7VEGF mice suggest
that vascular responses to VEGF-A differ in proximal and
peripheral lung and that these unique responses arise early
in lung development.
Effect of VEGF164 on early vascular net formation
Transgenic mice expressing the reporter gene -galacto-
sidase (LacZ) under control of the promoter for the VEGF
receptor VEGFR2 (flk-1) (Schactner et al., 2000) were used
to assess the effect of increased VEGF164 on embryonic
pulmonary vascular development. Whole-mount analysis of
E12.5 lungs from flk.LacZ mice demonstrated a vascular net
throughout the lung (Fig. 3A). The endothelial network
surrounded each peripheral lung bud, with only the most
distal margins of mesenchyme without gal staining (Fig.
3B). Analysis of thin sections confirmed that endothelial
cells encircled distal epithelial tubules (Fig. 3C).
SP-CrtTA/(tetO)7VEGF were bred to flk.LacZ mice.
Pregnant mice were treated with doxycycline from E10.5 to
E12.5 and the lungs analyzed at E12.5. This treatment
induces epithelial expression of VEGF164 in a period ear-
lier than in normal lung development. In these mice, endo-
thelial cells were absent from the mesenchyme surrounding
peripheral lung tubules and the vascular net surrounding
proximal tubules was disordered (Fig. 3D, E, and F). How-
ever, large vessels running parallel to the main stem bron-
chus were unaltered (arrow in Fig. 3D). In addition, epithe-
lial cell morphology (Fig. 3C, and F) and branching
morphogenesis (Fig. 3A and D) were unaltered. Immuno-
histochemistry for VEGF-A confirmed that distal epithelial
cells of SP-CrtTA/(tetO)7VEGF mice expressed VEGF-A
(Fig. 3G and H).
To test whether effects of VEGF-A on early lung mor-
phogenesis were reversible, nontransgenic and bitransgenic
SP-CrtTA/(tetO)7VEGF animals were treated with doxycy-
cline in utero from E10.5 to E12.5, then without doxycy-
cline until E16.5 (Fig. 3I and J). Vascular patterning was
normal in the SP-CrtTA/(tetO)7VEGF lung (Fig. 3J). Endo-
thelial cells encircled peripheral lung tubules, demonstrat-
ing reversibility of the abnormalities cased by VEGF164.
Vascular patterning can be reestablished following restora-
tion of normal VEGF-A levels.
Prolonged exposure to VEGF-A causes transcriptional
downregulation of VEGFR2 on endothelial cells in culture
(Wang et al., 2000). Therefore, the absence of gal staining
in the SP-CrtTA/(tetO)7VEGF/flk.LacZ lungs might be the
result of decreased activity of the VEGFR2 promoter-driven
LacZ transgene rather than the loss of endothelial cells.
However, analysis with another vascular marker, PECAM,
also indicated few endothelial cells in distal lung mesen-
chyme. In the experiment shown in Fig. 3K–N, E16.5 lungs
from bitrangenic SP-CrtTA/(tetO)7VEGF mice were ana-
lyzed following treatment with doxycycline from E10.5 to
E16.5. PECAM and VEGFR2 staining were coincident in
control lungs and restricted to blood vessels and the vascu-
lar net in nontransgenic (Fig. 3K and L) and SP-CrtTA/
(tetO)7VEGF lungs (Fig. 3M and N). However, in lungs of
SP-CrtTA/(tetO)7VEGF mice, the number of VEGFR2- and
PECAM-stained endothelial cells in peripheral lung was
decreased and the vascular patterning disrupted (Fig. 3M
and N). These data demonstrate that increased VEGF-A
expression by epithelial cells of distal lung decreased the
number of endothelial cells in the adjacent mesenchyme in
the SP-CrtTA/(tetO)7VEGF mice. These data demonstrate
that precise levels of VEGF-A are critical for normal lung
morphogenesis. Increased VEGF164 in the region around
distal epithelium appears to alter the process of vascular
assembly, perhaps inhibiting endothelial specification, pro-
liferation, and/or migration.
Vascular assembly and lung morphology were
permanently altered by increased VEGF164 after E12.5
When dams were treated with doxycycline from E12.5 to
E14.5 or E14.5 to E16.5, vascular patterning and airway
branching were severely altered at E16.5 (Fig. 4). Few
endothelial cells were detected in peripheral lung (Fig. 4E,
F, H, and I), with cells scattered within the mesenchyme but
not encircling the peripheral epithelial tubules (Fig. 4F and
I). Normally, in conducting airways, epithelial cells are
separated from endothelial cells by mesenchyme (Fig. 4C).
In airways of bitransgenic SP-CrtTA/(tetO)7VEGF mice,
endothelial cells were detected near the apical surface of
some peripheral tubules and larger bronchioli (arrows in
Fig. 4I), indicating malalignment of endothelial-epithelial
contacts. While abnormalities induced with a window of
increased VEGF164 between E10.5 and E12.5 were revers-
ible (Fig. 3J), increased expression of VEGF164 between
E12.5 and E14.5 irreversibly altered vascular pattern for-
mation at E16.5.
VEGF alters vascular assembly but not endothelial cell
proliferation or apoptosis
Since VEGF-A induces endothelial proliferation in vitro
(Conn et al., 1990) and in vivo (LeCouter et al., 2003),
increased VEGF-A expression might be predicted to in-
crease endothelial cell number. Immunostaining for BrdU
(Fig. 5A and B) indicated that expressing VEGF164 from
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E10.5 to E16.5 did not preferentially alter proliferation of
either mesenchymal or epithelial cell compartments. The
proliferation index, determined as the percentage of BrdU-
positive cells, was 22.5  4% in nontransgenic (n  8) and
22.3  6% in doxycycline-treated SP-CrtTA/(tetO)7VEGF
lungs (n  10).
Schachtner et al. (2000) used flk.LacZ transgenic mice to
quantify pulmonary vascular development, demonstrating
that gal activity in lysates was directly proportional to the
number of endothelial cells in tissues. We determined gal
activity in lungs from bitransgenic flk.LacZ animals to more
directly analyze the effect of VEGF164 on endothelial cell
number. Lysates were prepared from lungs of E12.5 SP-
CrtTA/(tetO)7VEGF/flk.LacZ embryos following exposure
to doxycycline from E10.5 to E12.5 and gal enzymatic
activity assayed. gal activity, normalized to total protein/
lung, was similar in lysates from E12.5 SP-CrtTA/
(tetO)7VEGF/flk.LacZ lungs and all other flk.LacZ lungs
(Fig. 5C), indicating equivalent numbers of endothelial
cells. The BrdU and gal analyses indicate equivalent num-
bers of endothelial cells in lung from nontransgenic and
doxycycline-induced SP-CrtTA/(tetO)7VEGF animals.
These data suggest that a 2- to 4-fold increase in VEGF-A
did not significantly increase endothelial cell proliferation in
developing lung.
VEGF also regulates endothelial cells through concen-
tration-dependent suppression of apoptosis (Gerber et al.,
1998). However, equivalent, low-level TUNEL staining
was detected in nontransgenic (NT) and SP-CrtTA/
(tetO)7VEGF lungs (Fig. 5D and E). Together these data
suggest that the effect of VEGF164 on the vascular network
in peripheral lung was not a consequence of changes in
endothelial cell proliferation or apoptosis. We propose that
increased epithelial expression of VEGF-A alters vascular
pattern formation through disruption of spatial cues required
for endothelial migration and participation in the formation
of the vascular net rather than by altering cell proliferation
or apoptosis.
VEGF-A disrupts pulmonary smooth muscle pattern
formation
As the pulmonary vasculature develops, vascular smooth
muscle cells (VSMC) assemble around large blood vessels
and encircle airway tubules that form conducting airways.
VSMC arise through differentiation of mesenchymal cells
influenced by factors including TGF- and PDGF (Hell-
strom et al., 1999; Yang et al., 1999). In vitro analysis
suggests VSMC also respond to VEGF-A (Ishida et al.,
2001; Parenti et al., 2002). Immunohistochemistry for
smooth muscle (SM)  actin was used to determine whether
VSMC development and pattern formation were altered by
increased VEGF-A (Fig. 6). In normal E16.5 lung (Fig. 6A
and B), VSMC surrounded developing bronchi and bron-
chioli. In the pulmonary vasculature, VSMC form concen-
tric rings consisting of two to three layers that surround
large blood vessels (Fig. 6B). A single layer of VSMC
surround small vessels with lumens. The nonoverlapping
pattern of SM  actin and PECAM expression in distal lung
(compare Fig. 2B and Fig. 6A) illustrate that VSMC do not
accompany the peripheral vascular net or distal airway tu-
bules at E16.5.
Increased expression of VEGF164 severely disrupted the
pattern of SM  actin staining (Fig. 6C and D). VSMC were
associated with the abnormal dilated epithelial tubules, but
the proximal to distal pattern was altered from that of
normal lung. In some areas adjacent to bronchial epithelium
VSMC were absent, while in other areas VSMC were
present but arranged in multiple layers (Fig. 6C). In distal
mesenchyme the number of SM  actin-positive cells was
increased. Endothelial cells were absent from these same
regions (Fig. 4E, F, H, and I). Increased numbers of VSMC
were observed surrounding large blood vessels in lungs of
SP-CrtTA/(tetO)7VEGF mice (Fig. 6C). These data suggest
that precise regulation of VEGF-A is also critical for VSMC
pattern formation in the embryonic lung.
VEGF164 perturbs branching morphogenesis
E12.5 to E16.5 was a critical period during which
VEGF-A altered branching morphogenesis. Expression of
VEGF164 from E12.5 to E14.5 or E14.5 to E16.5 resulted
in decreased branching and dilation of peripheral lung tu-
bules (Fig. 4D and G) at E16.5. In control lung, distal
epithelial cells have strong expression of proSP-C (Wert et
al., 1993) while the subset of epithelial cells between
branches has relatively less proSP-C staining (Fig. 6E). In
the dilated tubules of SP-CrtTA/(tetO)7VEGF, proSP-C was
detected in clusters of epithelial cells separated by subsets
of cells with diminished expression. These data indicate that
epithelial differentiation was not affected by increased
VEGF-A but that the process of branching morphogenesis
was inhibited. E12.5 to E16.5 is a critical period during
which precise regulation of VEGF-A level is required for
normal epithelial pattern formation.
Discussion
During lung morphogenesis, increased VEGF164 alters
vascularization, branching morphogenesis, and smooth
muscle patterning. Disruption of vascular patterning was
independent of cell proliferation or apoptosis. We demon-
strate that changes in the temporal and spatial expression of
VEGF164 alter endothelial assembly and disrupt vascular
pattern formation.
VEGF gradients and endothelial cell migration
VEGF-A regulates cellular properties required for mi-
gration including invasive activity, motility, and adhesion/
deadhesion to matrix substrates. During development,
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VEGF-A is required for guidance of endothelial progenitors
to the appropriate sites where they undergo differentiation
(Traver and Zon, 2002). The high affinity of VEGF188 and
VEGF164 for heparan sulfate components of extracellular
matrix has led to a model for the role of VEGF-A in
alveolar-capillary alignment (Ng et al., 2001; Park et al.,
1993). In this model, localized areas of increased VEGF-A
expression by distal epithelium are predicted to establish a
gradient around the tips of developing airways. The gradient
directs endothelial cell migration, vascular assembly, and
subsequent alignment of distal epithelium and the vascular
net. This acinar unit develops into the alveolar-capillary
complex required for gas exchange. We propose that in-
creased expression of VEGF164 eliminates this local con-
centration gradient and disrupts endothelial cell specifica-
tion and migration.
Several lines of evidence suggest that disruption of vas-
cular assembly may be regulated through VEGFR1. Mice
with null mutations in vegfr-1 gene have disorganized vas-
cular development with lethality by E9.0 (Fong et al., 1995,
1999). Endothelial cell progenitor recruitment and migra-
tion are mediated through VEGFR1, while mitogenic and
angiogenic effects of VEGF-A are mediated through
VEGFR2 (Ferrara, 2001). Unclear is whether it is the dif-
ferential distribution of VEGF-A or the absolute level of the
factor that induces signaling critical for appropriate endo-
thelial cell migration. Assembly and/or maintenance of the
vascular net appears to be very sensitive to VEGF-A con-
centrations, as in vivo levels were only induced by 2.5- to
4-fold. Miquerol et al. (2000) showed that a similar 2- to
3-fold increase in VEGF-A induces lethal defects in heart
development.
VEGF-A isoform-specific responses in lung
Mice selectively expressing single VEGF-A isoforms
have been developed through targeted exon deletion (Car-
meliet et al., 1999; Ng et al., 2001; Stalmans et al., 2002).
These animals express the individual isoforms at levels
similar to the total amount of all isoforms in nontransgenic
(VEGF/) mice. Survival, litter size, and pulmonary de-
velopment of mice exclusively expressing the VEGF164
isoform (VEGF164/164 mice) were indistinguishable from
VEGF/ animals. VEGF188/188 mice have decreased sur-
vival and breeding but pulmonary development is reported
to be normal (Stalmans et al., 2002). However, while
VEGF188/188 mice have normal venular development, ar-
terial development is impaired. VEGF120/120 mice die
either in utero or as neonates (Carmeliet et al., 1999). A
portion of these animals die of respiratory distress. The
lungs of VEGF120/120 mice have defects in microvascula-
ture including altered pattern formation and delayed pulmo-
nary development (Galambos et al., 2002; Ng et al., 2001).
As total VEGF-A levels are not affected, the defects in
pulmonary development may be attributed to isoform-spe-
cific characteristics. VEGF120 is highly diffusible and we
suggest that in VEGF120/120 lungs the poor capillary de-
velopment is the consequence of uniform, rather than dif-
ferential distribution of VEGF-A and the failure to develop
a VEGF-A gradient morphogenic for endothelial cells. The
survival of VEGF164/164 mice suggests that lung organo-
Fig. 5. VEGF-A induction did not alter endothelial cell proliferation or
apoptosis. (A and B) Proliferation was detected by immunostaining after
2-h incorporation of BrdU in embryos doxycycline-treated from E10.5 to
E16.5 for lungs from (A) nontransgenic and (B) SP-CrtTA/(tetO)7VEGF
animals. The proliferation index was determined as the percentage of
BrdU cells (n 4 animals/group). gal activity was determined for E12.5
lung lysates from animals treated in utero from E10.5 to E12.5 with
doxycycline. gal activity as OD units was normalized to total protein per
lung. Data were derived from analysis of four doxycycline-treated litters
with SP-CrtTA/(tetO)7VEGF/flk.LacZ lungs (n  10) compared to a group
of littermates including flk.LacZ, SP-CrtTA/flk.LacZ, and (tetO)7VEGF/
flk.LacZ lungs (n 8). In the latter group, animals are flk/lacZ with a single
transgene, either SP-CrtTA or (tetO)7VEGF, and therefore without in-
creased VEGF-A. TUNEL-positive cells are indicated with arrows. (D and
E) Apoptosis was detected by TUNEL immunostaining.
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genesis is normal and that VEGF164 alone at typical levels
provides the cues necessary for normal vessel development.
The severe defects in the SP-CrtTA/(tetO)7VEGF mice may
reflect responses to both increased VEGF164 and disruption
of VEGF-A gradients.
Effects of VEGF-A are temporally and spatially restricted
The effects of VEGF-A on vascular net assembly are
also dependent on the time and the location of induction.
Early disruption of vascular assembly (e.g., before E12.5)
but not later disruption is reversible. Embryonic day 12
marks the transition from the embryonic stage to the pseu-
doglandular stage of development. The reversibility of the
effects of VEGF-A on vascular assembly may be deter-
mined by the stage of functional differentiation of the en-
dothelial cells. In the embryonic and early pseudoglandular
stage, endothelial cells are still being recruited from angio-
blast populations in the peripheral lung through vasculogen-
esis. Later, when the cells are part of a well-established
vascular net, they acquire the specificity needed for capil-
lary, arterial, venous, and lymphatic function. We propose
that early in lung morphogenesis, endothelial cells within
the vascular net are not fully differentiated and are able to
reassemble or repair when normal VEGF-A levels are re-
stored. Later in development, perhaps after vascular speci-
fication, effects of increased VEGF-A are not reversible.
CCSP-driven expression in proximal lung-induced evag-
ination of the epithelium into the lumens of large airways.
Capillary-like structures accompanied the evaginated epi-
thelium. This morphology was very different from the dis-
ruption to vascular patterning seen when VEGF164 was
expressed by peripheral epithelium. The vascular beds of
proximal and distal lung are distinct in origin, composition,
and physiological response (deMello et al, 1997). There-
fore, the distinct phenotypes for SP-CrtTA/(tetO)7VEGF
and CCSPrtTA/(tetO)7VEGF may reflect early establish-
ment of differential responses of endothelial cells in prox-
imal and peripheral vascular beds.
In the experiments described here, tissue VEGF-A was
increased 2- to 4-fold in both SP-CrtTA/(tetO)7VEGF and
CCSPrtTA/(tetO)7VEGF transgenic mice. (Shehata et al.,
Fig. 6. VEGF-A disrupts pulmonary smooth muscle patterning and airway branching. (A–D) Immunohistochemistry for SM  actin and (E and F) proSP-C
for E16.5 lung from mice treated in utero from E10.5 to E16.5 with doxycycline. (A and B) In nontransgenic and (C and D) SP-CrtTA/(tetO)7VEGF lung,
VSMC encircled bronchi (br) and vessels (v), but did not completely encircle peripheral tubules (epi). (C and D) In SP-CrtTA/(tetO)7VEGF lungs the pattern
of VSMC in distal lung was disrupted (C), with displacement of VSMC from bronchi (br) as indicated with arrows and from distal epithelial (epi) tubules
indicated by arrowheads. (E and F) ProSP-C was detected in subsets of distal epithelial cells indicated by arrowheads in both (E) nontransgenic and (F)
SP-CrtTA/(tetO)7VEGF lung.
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1999) demonstrate 2- to 3-fold increase in the level of
immunoreactive VEGF-A in the lungs of infants with con-
genital diaphragmatic hernia (CDH). Lungs of these infants
have few bronchial branches, reduced pulmonary vascular
network, and misalignment of airway epithelium and cap-
illary vessels. This suggests that the modest 2- to 4-fold
increase in VEGF-A and the severe vascular abnormalities
seen in the SP-CrtTA/(tetO)7VEGF animals is physiologi-
cally relevant.
VEGF-A has been suggested as a potential therapeutic
agent to induce maturation in respiratory distress syndrome
(RDS). RDS is responsible for 50% of the mortality in
preterm infants. In RDS, pulmonary function is compro-
mised by delayed maturation. A recent report suggests that
VEGF treatment can induce lung maturation and improve
lung function and survival in animal models (Compernolle
et al., 2002). Intratracheal administration of VEGF in pre-
term mice with RDS improved breathing and accelerated
alveolar development without inducing pulmonary vascular
leakage or bleeding (Compernolle et al., 2002). However,
our findings demonstrating abnormal morphology of con-
ducting airways following in vivo induction of modest lev-
els of VEGF-A in the bronchus and bronchioli, indicates
caution in use of VEGF as a therapeutic agent for neonates.
VEGF and airway epithelial and VSMC development
VEGF164 caused distinctive pulmonary dysplasia with
dilated peripheral airway tubules and altered VSMC pat-
terning. VSMC proliferate in vitro in response to VEGF-A
(Ishida et al., 2001; Parenti et al., 2002). Altered VSMC
patterning on VEGF164 expression may be the result of
increased VSMC proliferation. However, BrdU analysis in-
dicated no differential proliferation of VSMC or other cell
types on VEGF164 expression. Cell type-specific analysis is
required to definitively determine if VSMC proliferate in
vivo in response to VEGF164.
VEGF-induced dysplasia is not the result of inappropri-
ate epithelial proliferation or premature differentiation but
rather may be the consequence of altered branching mor-
phogenesis. It is unclear whether VEGF-A affects airway
branching through direct or indirect effects on epithelial
cells. VEGF-A has been considered an endothelial-specific
growth factor. Using immunohistochemistry for PECAM
and VEGFR2, we detected VEGFR2 only on vascular struc-
tures throughout lung development (E16.5 lung shown in
Fig. 3L). Staining was not detected on respiratory epithelial
cells. In addition, gal staining was detected in endothelial
but not epithelial cells by both whole-mount and thin-sec-
tion analysis of E12.5 lungs from flk.LacZ animals (Fig. 3).
Finally, in situ analysis for VEGFR2 (Gebb and Shannon,
2000) and VEGFR1 mRNA (Akeson, A.L., unpublished
data) demonstrated that only endothelial cells expressed
these receptors. Together these data suggest that airway
dysplasia in embryonic lung was not a result of direct
effects of VEGF-A on epithelial cells. We propose that
altered lung morphogenesis is an indirect consequence of
dysregulation of vascular assembly, perhaps altering ex-
pression of modulators critical for signaling from endothe-
lium to developing airway epithelium and pulmonary
VSMC. Our studies demonstrate that VEGF-A controls
vascular assembly and suggests that the pulmonary vascular
net plays a specific inductive role during lung organogene-
sis.
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